News on this topic
Profile picture of Reuters
Reuters
Credibility A
 Oct 10 25
Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says: Johnson & Johnson is in discussions to buy Protagonist Therapeutics ...
reuters.com/business/healthcare-pharmaceuticals/johnson-johnson-talks-acquire-protagonist-therapeutics-wsj-reports-2025-10-10/
Johnson & Johnson in talks to acquire Protagonist Therapeutics ...
21
8 4
Similar to This
Previous
0
1
0
0
0
0
Profile picture of Common Dreams
Common Dreams
C−
 Oct 22
Meet the Corporations Funding Ramaswamy's Vicious Attack Ad on Acton: Corporate PACs for Bank of America, Deloitte, Kroger, Pfizer, Johnson & Johnson ...
commondreams.org/news/ramaswamy-attack-ad-corporations
Meet the Corporations Funding Ramaswamy's Vicious Attack Ad on Acton
0 similar articles
4
2
Profile picture of Inc.com
Inc.com
B
 Oct 21
Hundreds of Californians Just Sued Carefree Over PFAS. Now the Case Hinges on 2 Words
inc.com/lucia-auerbach/californians-just-sued-carefree-over-pfas-now-case-hinges-2-words/91423490
Hundreds of Californians Just Sued Carefree Over PFAS. Now the Case Hinges ...
0 similar articles
0
1
0
2
Profile picture of op-online.de
op-online.de
C
 Oct 21
Ovarian cancer due to talcum powder? Sufferers in Great Britain fight for answers in court
op-online.de/welt/eierstockkrebs-wegen-babypuder-betroffene-kaempfen-gericht-talkum-johnson-and-johnson-zr-94549669.html
Ovarian cancer due to talcum powder? Sufferers in Great Britain fight for ...
0 similar articles
0
0
0
2
2
4
Profile picture of Die Presse
Die Presse
B
 Sep 08
Multiple Myeloma: A Cure in Sight?: In Austria, approximately 2,500 people are affected by multiple myeloma*. For this disease, which used to be almost a death ...
diepresse.com/38640598/multiples-myelom-heilung-in-sicht
Multiple Myeloma: A Cure in Sight?
0 similar articles
0
0
Profile picture of STAT
STAT May 05
Are analysts too quick to gloss over Lilly’s liver case?: Today's biotech news covers Cytokinetics' Myqorzo's trial results ...
statnews.com/2026/05/05/biotech-news-analysts-glossing-over-eli-lilly-liver-case/
Are analysts too quick to gloss over Lilly’s liver case?
0 similar articles
0
0
Profile picture of STAT
STAT May 05
Johnson & Johnson advances IBD therapy, despite trial miss: A closely watched combination therapy developed by Johnson & Johnson failed to show a statistically ...
statnews.com/2026/05/05/johnson-and-johnson-ibd-therapy-no-meaningful-improvement/
Johnson & Johnson advances IBD therapy, despite trial miss
0 similar articles
0
0
Profile picture of CNBC
CNBC
B
 Mar 18
FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi: Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily ...
cnbc.com/2026/03/18/icotyde-psoriasis-pill-from-jj-to-rival-tremfya-skyrizi-il-23-shots.html
FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
1 similar article
1
2 0
Profile picture of Reuters
Reuters
A
 Nov 17 25
J&J expands cancer portfolio with $3.05 billion Halda buy: Johnson & Johnson said on Monday it would buy privately held Halda Therapeutics for $3 ...
reuters.com/legal/transactional/jj-buy-cancer-therapy-developer-halda-therapeutics-305-billion-2025-11-17/
J&J expands cancer portfolio with $3.05 billion Halda buy
1 similar article
6
10 5
Profile picture of deraktionaer.de
deraktionaer.de
C
 Nov 07 25
Johnson & Johnson: Double whammy – billion-dollar acquisition pays off: Johnson & Johnson receives FDA approval for Caplyta for the treatment of severe ...
deraktionaer.de/artikel/pharma-biotech/johnson-johnson-doppelschlag-milliardenschwere-uebernahme-zahlt-sich-aus-20389957.html
Johnson & Johnson: Double whammy – billion-dollar acquisition pays off
0 similar articles
0
0
1
0
Profile picture of marketwatch.com
marketwatch.com
B
 Oct 15 25
Johnson & Johnson’s stock heads for a record after a profit beat and plans for another spinoff
marketwatch.com/story/johnson-johnsons-stock-heads-for-a-record-after-a-profit-beat-and-plans-for-another-spinoff-af403f00
Johnson & Johnson’s stock heads for a record after a profit beat and plans ...
0 similar articles
0
5
Profile picture of The Wall Street Journal
The Wall Street Journal
B
 Oct 14 25
Johnson & Johnson to Split Off Orthopedics Business: Its artificial hip and knee replacement division to become a stand-alone company within 18 to 24 months
wsj.com/health/healthcare/johnson-johnson-to-split-off-orthopedics-business-2b9f3d62
Johnson & Johnson to Split Off Orthopedics Business
0 similar articles
0
4
Profile picture of deraktionaer.de
deraktionaer.de
C
 Aug 29 25
Johnson & Johnson: Massive study setback: Johnson & Johnson halts development of Nipocalimab for RA after Phase 2a failure.
deraktionaer.de/artikel/pharma-biotech/johnson-johnson-massiver-studienrueckschlag-20385648.html
Johnson & Johnson: Massive study setback
0 similar articles
0
0
Profile picture of The Wall Street Journal
The Wall Street Journal
B
 Jul 07 25
The MAHA Movement Loves Psychedelics. Should Wall Street?: A nasal spray for treatment-resistant depression has delivered strong clinical results and rekindled ...
wsj.com/health/pharma/psychedelic-drugs-investment-maha-f4b7dff0
The MAHA Movement Loves Psychedelics. Should Wall Street?
1 similar article
4
20
Next